晚期乳腺癌紫杉类耐药及其新型抗微管治疗

doi:10.3760/cma.j.issn.1673-422X.2016.08.015

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (8): 622-624.doi: 10.3760/cma.j.issn.1673-422X.2016.08.015

晚期乳腺癌紫杉类耐药及其新型抗微管治疗

黄圆,刘丹丽,王晓稼

310022 杭州，浙江省肿瘤医院化疗中心

出版日期:2016-08-08 发布日期:2016-07-05
通讯作者: 王晓稼，Email: wxiaojia0803@163.com E-mail:wxiaojia0803@163.com
基金资助:
浙江省自然科学基金（LQ14H160004）

Taxane resistance in metastatic breast cancer and novel microtubuletargeting agents

Huang Yuan, Liu Danli, Wang Xiaojia

Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China

Online:2016-08-08 Published:2016-07-05
Contact: Wang Xiaojia, Email: wxiaojia0803@163.com E-mail:wxiaojia0803@163.com
Supported by:
Natural Science Foundation of Zhejiang Province of China (LQ14H160004)

摘要/Abstract

摘要： 紫杉类药物原发性或继发性耐药已成为不可避免的棘手难题。伊沙匹隆对经多线治疗包括紫杉类耐药的乳腺癌患者有效。艾日布林用于治疗接受过二线以上化疗的晚期乳腺癌患者。新型抗微管药物有望成为既往接受过紫杉类药物标准化疗的晚期乳腺癌患者的有效方案。

关键词: 乳腺肿瘤, 紫杉烷类, 抗药性, 微管

Abstract: The development of primary or acquired taxane resistance inevitably becomes to be the main problem. Ixabepilone is effective in metastatic breast cancer (MBC) patients including those heavily pretreated or resistant to taxanes. Eribulin has been used for the treatment of MBC patients who have received at least two prior chemotherapy regimens. New microtubuletargeting agents are promising to be effective options for patients progressing after standard taxanecontaining chemotherapy.

Key words: Breast neoplasms, Taxoids, Drug resistance, Microtubules

黄圆,刘丹丽,王晓稼. 晚期乳腺癌紫杉类耐药及其新型抗微管治疗[J]. 国际肿瘤学杂志, 2016, 43(8): 622-624.

Huang Yuan, Liu Danli, Wang Xiaojia. Taxane resistance in metastatic breast cancer and novel microtubuletargeting agents[J]. Journal of International Oncology, 2016, 43(8): 622-624.

参考文献

［1］ Barbuti AM, Chen ZS. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy［J］. Cancers (Basel), 2015, 7(4): 2360-2371. DOI: 10.3390/cancers7040897. ［2］吴静, 杨睿, 刘树业. 肿瘤多药耐药的产生机制及逆转策略［J］. 国际肿瘤学杂志, 2013, 40(12): 889-892. DOI: 10.3760/cma.j.issn.1673-422X.2013.12.003. ［3］ Karki R, Mariani M, Andreoli M, et al. βⅢTubulin: biomarker of taxane resistance or drug target?［J］. Expert Opin Ther Targets, 2013, 17(4): 461-472. ［4］ Kavallaris M. Microtubules and resistance to tubulinbinding agents［J］. Nat Rev Cancer, 2010, 10(3): 194-204. DOI: 10.1038/nrc2803. ［5］ Rohena CC, Mooberry SL. Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities［J］. Nat Prod Rep, 2014, 31(3): 335-355. DOI: 10.1039/c3np70092e. ［6］ Nobili S, Landini I, Mazzei T, et al. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression［J］. Med Res Rev, 2012, 32(6): 1220-1262. DOI: 10.1002/med.20239. ［7］ Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone［J］. Cancer Chemother Pharmacol, 2009, 63(2): 201-212. DOI: 10.1007/s00280-008-0727-5. ［8］ Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase Ⅱ study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine［J］. J Clin Oncol, 2007, 25(23): 3407-3414. DOI: 10.1200/JCO.2006.09.3849. ［9］ Thomas E, Tabernero J, Fornier M, et al. Phase Ⅱ clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxaneresistant metastatic breast cancer［J］. J Clin Oncol, 2007, 25(23): 3399-3406. DOI: 10.1200/JCO.2006.08.9102. ［10］ Hortobagyi GN, Gomez HL, Li RK, et al. Analysis of overall survival from a phase Ⅲ study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes［J］. Breast Cancer Res Treat, 2010, 122(2): 409-418. DOI: 10.1007/s10549-010-0901-4. ［11］ Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase Ⅲ trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2010, 28(20): 3256-3263. DOI: 10.1200/JCO.2009.24.4244. ［12］ Roché H, Conte P, Perez EA, et al. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase Ⅲstudies［J］. Breast Cancer Res Treat, 2011, 125(3): 755-765. DOI: 10.1007/s10549-010-1251-y. ［13］ Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents［J］. Clin Breast Cancer, 2010, 10(1): 64-73. DOI: 10.3816/CBC.2010.n.009. ［14］ Chuang E, Wiener N, Christos P, et al. Phase Ⅰtrial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary［J］. Ann Oncol, 2010, 21(10): 2075-2080. ［15］ Moulder S, Li H, Wang M, et al. A phaseⅡ trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2positive metastatic breast cancer: an eastern cooperative oncology group trial［J］. Breast Cancer Res Treat, 2010, 119(3): 663-671. DOI: 10.1007/s10549-009-0658-9. ［16］ Vahdat LT, Pruitt B, Fabian CJ, et al. Phase Ⅱ study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2009, 27(18): 2954-2961. DOI: 10.1200/JCO.2008.17.7618. ［17］ Cortes J, Vahdat L, Blum JL, et al. Phase Ⅱstudy of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine［J］. J Clin Oncol, 2010, 28(25): 3922-3928. DOI: 10.1200/JCO.2009.25.8467. ［18］ Cortes J, O′shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician′s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study［J］. Lancet, 2011, 377(9769): 914-923. DOI: 10.1016/S0140-6736(11)60070-6. ［19］ Kaufman PA, Awada A, Twelves C, et al. Phase Ⅲ open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2015, 33(6): 594-601. DOI: 10.1200/JCO.2013.52.4892.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[5]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[6]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[7]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[8]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[9]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[10]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[11]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[12]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[13]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[14]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[15]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.

晚期乳腺癌紫杉类耐药及其新型抗微管治疗

Taxane resistance in metastatic breast cancer and novel microtubuletargeting agents

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价